ITRM20040395A1 - Composizione comprendente statine e acidi grassi omega 3. - Google Patents

Composizione comprendente statine e acidi grassi omega 3.

Info

Publication number
ITRM20040395A1
ITRM20040395A1 IT000395A ITRM20040395A ITRM20040395A1 IT RM20040395 A1 ITRM20040395 A1 IT RM20040395A1 IT 000395 A IT000395 A IT 000395A IT RM20040395 A ITRM20040395 A IT RM20040395A IT RM20040395 A1 ITRM20040395 A1 IT RM20040395A1
Authority
IT
Italy
Prior art keywords
statines
fatty acids
composition including
acids omega
omega
Prior art date
Application number
IT000395A
Other languages
English (en)
Italian (it)
Inventor
Per Il Credito Sportivo Istituto
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000395A priority Critical patent/ITRM20040395A1/it
Publication of ITRM20040395A1 publication Critical patent/ITRM20040395A1/it
Priority to SI200531865T priority patent/SI1773312T1/sl
Priority to HK07111294.3A priority patent/HK1105871B/xx
Priority to NZ552396A priority patent/NZ552396A/en
Priority to CN2005800258385A priority patent/CN1993119B/zh
Priority to US11/632,953 priority patent/US8853229B2/en
Priority to CA2573000A priority patent/CA2573000C/en
Priority to JP2007524466A priority patent/JP5103179B2/ja
Priority to PT57694861T priority patent/PT1773312E/pt
Priority to PL05769486T priority patent/PL1773312T3/pl
Priority to KR1020077004538A priority patent/KR101355122B1/ko
Priority to PCT/IT2005/000414 priority patent/WO2006013602A1/en
Priority to ES05769486.1T priority patent/ES2481169T3/es
Priority to MX2007001009A priority patent/MX2007001009A/es
Priority to BRPI0514026-9A priority patent/BRPI0514026A/pt
Priority to EP05769486.1A priority patent/EP1773312B1/en
Priority to AU2005268402A priority patent/AU2005268402B2/en
Priority to EA200700240A priority patent/EA014444B1/ru
Priority to DK05769486.1T priority patent/DK1773312T3/da
Priority to IL180602A priority patent/IL180602A/en
Priority to ZA200701816A priority patent/ZA200701816B/en
Priority to CY20141100583T priority patent/CY1115416T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000395A 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3. ITRM20040395A1 (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.
DK05769486.1T DK1773312T3 (da) 2004-08-03 2005-07-19 Sammensætning omfattende statiner og omega-3-fedtsyrer
KR1020077004538A KR101355122B1 (ko) 2004-08-03 2005-07-19 스타틴 및 오메가 3 지방산 함유 조성물
ES05769486.1T ES2481169T3 (es) 2004-08-03 2005-07-19 Composición que contiene estatinas y ácidos grasos omega-3
NZ552396A NZ552396A (en) 2004-08-03 2005-07-19 Composition containing simvastatin, coenzyme Q10, resveratrol, pantethine and omega-3 fatty acids
CN2005800258385A CN1993119B (zh) 2004-08-03 2005-07-19 含他汀类药物和ω-3脂肪酸的组合物
US11/632,953 US8853229B2 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
CA2573000A CA2573000C (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
JP2007524466A JP5103179B2 (ja) 2004-08-03 2005-07-19 スタチンおよびオメガ−３脂肪酸を含む組成物
PT57694861T PT1773312E (pt) 2004-08-03 2005-07-19 Composição contendo estatinas e ácidos graxos ómega-3
PL05769486T PL1773312T3 (pl) 2004-08-03 2005-07-19 Kompozycja zawierająca statyny i kwasy tłuszczowe omega-3
SI200531865T SI1773312T1 (sl) 2004-08-03 2005-07-19 Sestavek, ki vsebuje statine in maščobne kisline omega-3
PCT/IT2005/000414 WO2006013602A1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
HK07111294.3A HK1105871B (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
MX2007001009A MX2007001009A (es) 2004-08-03 2005-07-19 Composicion que contiene estatinas y acidos grasos omega-3.
BRPI0514026-9A BRPI0514026A (pt) 2004-08-03 2005-07-19 composição contendo estatinas e ácidos graxos Èmega-3
EP05769486.1A EP1773312B1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
AU2005268402A AU2005268402B2 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
EA200700240A EA014444B1 (ru) 2004-08-03 2005-07-19 Композиция, содержащая статины и омега-3 жирные кислоты
IL180602A IL180602A (en) 2004-08-03 2007-01-08 An ingredient containing statins and omega-3 fatty acids
ZA200701816A ZA200701816B (en) 2004-08-03 2007-03-01 Composition containing statins and omega -3 fatty acids
CY20141100583T CY1115416T1 (el) 2004-08-03 2014-07-16 Συνθεση που περιεχει στατινες και ωμεγα-3 λιπαρα οξεα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.

Publications (1)

Publication Number Publication Date
ITRM20040395A1 true ITRM20040395A1 (it) 2004-11-03

Family

ID=35124288

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.

Country Status (21)

Country Link
US (1) US8853229B2 (enExample)
EP (1) EP1773312B1 (enExample)
JP (1) JP5103179B2 (enExample)
KR (1) KR101355122B1 (enExample)
CN (1) CN1993119B (enExample)
AU (1) AU2005268402B2 (enExample)
BR (1) BRPI0514026A (enExample)
CA (1) CA2573000C (enExample)
CY (1) CY1115416T1 (enExample)
DK (1) DK1773312T3 (enExample)
EA (1) EA014444B1 (enExample)
ES (1) ES2481169T3 (enExample)
IL (1) IL180602A (enExample)
IT (1) ITRM20040395A1 (enExample)
MX (1) MX2007001009A (enExample)
NZ (1) NZ552396A (enExample)
PL (1) PL1773312T3 (enExample)
PT (1) PT1773312E (enExample)
SI (1) SI1773312T1 (enExample)
WO (1) WO2006013602A1 (enExample)
ZA (1) ZA200701816B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
US20060211763A1 (en) * 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
WO2007042272A2 (en) * 2005-10-14 2007-04-19 Dsm Ip Assets B.V. Use of a nutraceutical composition comprising resveratrol for the treatment of age-related diseases
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
ES2769926T3 (es) 2009-02-10 2020-06-29 Amarin Pharmaceuticals Ie Ltd Ester etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
CA2765329C (en) * 2009-06-12 2018-01-02 Calanus As Oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN102665698A (zh) 2009-12-23 2012-09-12 迪菲安特制药有限责任公司 可用于治疗心血管疾病的联合组合物
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP3036999B1 (en) 2010-12-20 2019-04-24 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
AU2015201809B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013240427B2 (en) * 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
EP2875359A4 (en) * 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015003246A1 (en) * 2013-07-09 2015-01-15 Mcmaster University Combination of a statin with an inflammasome inhibitor
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
RU2554806C1 (ru) * 2014-07-29 2015-06-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа
CN104922160A (zh) * 2015-05-22 2015-09-23 舟山三合生物科技有限公司 他汀与Omega-3脂肪酸和辅酶Q10复配的组合物及其应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3810104B1 (en) 2018-04-16 2024-03-06 S&R Farmaceutici S.p.A. Mixture of resveratrol supported on magnesium hydroxide and non-supported pure resveratrol for treating female fertility
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055638C (zh) * 1995-07-14 2000-08-23 李江 富硒虫草口服液及其制备方法
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US20030228393A1 (en) * 2002-05-31 2003-12-11 Zhao Iris Ginron Multi-phase food & beverage
CN1061259C (zh) * 1998-11-24 2001-01-31 彭素萍 藜蒿中生物活性物质的富集物及用途
EP1339429A4 (en) * 2000-11-29 2007-03-14 Smithkline Beecham Corp COMPOSITION CONTAINING STATINS AND CALCIUM FOR IMPROVING CARDIOVASCULAR HEALTH
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20020182585A1 (en) 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US6855353B2 (en) * 2002-03-08 2005-02-15 Yaguang Liu Method for producing antioxidant and prevention of cancer
AU2003266287A1 (en) * 2002-08-23 2004-03-11 Dsm Ip Assets B.V. Novel nutraceutical compositions comprising biotin
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
JP2006508096A (ja) 2002-11-07 2006-03-09 ディーエスエム アイピー アセッツ ビー．ブイ． 没食子酸エピガロカテキンを含む新規な栄養補助組成物

Also Published As

Publication number Publication date
CA2573000C (en) 2014-03-11
IL180602A0 (en) 2008-03-20
JP2008509132A (ja) 2008-03-27
PT1773312E (pt) 2014-07-25
CN1993119A (zh) 2007-07-04
EA200700240A1 (ru) 2007-06-29
EP1773312A1 (en) 2007-04-18
CY1115416T1 (el) 2017-01-04
WO2006013602A1 (en) 2006-02-09
KR20070058460A (ko) 2007-06-08
MX2007001009A (es) 2007-04-16
US8853229B2 (en) 2014-10-07
EP1773312B1 (en) 2014-05-07
EA014444B1 (ru) 2010-12-30
CN1993119B (zh) 2011-04-06
SI1773312T1 (sl) 2014-08-29
NZ552396A (en) 2009-08-28
IL180602A (en) 2015-06-30
CA2573000A1 (en) 2006-02-09
BRPI0514026A (pt) 2008-05-27
AU2005268402A1 (en) 2006-02-09
PL1773312T3 (pl) 2014-09-30
DK1773312T3 (da) 2014-07-21
AU2005268402B2 (en) 2010-08-26
HK1105871A1 (en) 2008-02-29
US20080089876A1 (en) 2008-04-17
KR101355122B1 (ko) 2014-02-04
ZA200701816B (en) 2008-07-30
JP5103179B2 (ja) 2012-12-19
ES2481169T3 (es) 2014-07-29

Similar Documents

Publication Publication Date Title
ITRM20040395A1 (it) Composizione comprendente statine e acidi grassi omega 3.
DK1663936T3 (da) Biaryloxymethylaren-carboxylsyrer
NO20054958D0 (no) Substitulerte aminokarboksylsyrer
NO20054957D0 (no) Subtituerte karboksylsyrer
EP1861087A4 (en) TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
FI20031301L (fi) Esteröintimenetelmä
IL192366A0 (en) Omega 3 fatty acid formulations
ATE517887T1 (de) Neue 2-pyridincarbonsäureamidderivate
EE200300030A (et) 4-jodofenüülaminobenshüdroksaamhapete oksügeenitud estrid
SM200600001S (it) Modello ornamentale multiplo costituito da 5 seriedi caratteri tipografici
DE502004009971D1 (de) Acylierte nonadepsipeptide vom lysobactin-typ
ATE439362T1 (de) Ester in position 20 von camptothecinen
NO20054747D0 (no) Fosforsyreester-demulgerende sammensetning
ATE432918T1 (de) Verfahren zur herstellung von cpla 2-inhibitoren
DE60336726D1 (de) Hafniumsilicid-target und verfahren zu seiner herstellung
DE60143052D1 (de) Lipid vom carbonsäuretyp
DE502004001633D1 (de) Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
FI20020593A0 (fi) Menetelmä konjugoidun linolihapon valmistamiseksi
DE602006014845D1 (de) Zweistufiges verfahren zur herstellung von fettsäuren
FR2905066B1 (fr) Procede de peeling a base de tensioactifs et d&#39;acides
ITMI20020750A1 (it) Acidi grassi essenziali nel trattamento di cardiopatie
DE50114934D1 (de) Verfahren zur Ermittlung der Nettofallhöhe von Turbinen
DE602006008223D1 (de) Verfahren zur Herstellung von Fettsäuren
NO20022578D0 (no) Fosfolipider inneholdende omega-3 fettsyrer
ITMI20020825A1 (it) Ottenimento di esteri alchilici da trigliceridi di origine animale o vegetale in presenza di acidi grassi liberi